Immunai Stock
HealthTechLooking to sell Immunai stock or options?
Contact usImmunai, a developer of immune system technology, is designed to deliver treatments for oncology and auto-immune disorders. Utilizing single-cell biology, AI, and machine learning, Immunai's platform combines exhaustive mapping and reprogramming of the immune system, providing fresh insights into the immune system. This empowers healthcare researchers to expedite drug development and enhance patient outcomes.
Meron Capital, Endless Frontier Labs, 8VC, Alexandria Venture Investments, Gefen Capital, Perot Jain, Dexcel Pharma, Piedmont Capital Investments, Talos Ventures, Duquesne Family Office, iAngels, TLV Partners, Schusterman Family Investments, ICON (Palo Alto), R-Squared Ventures, Koch Disruptive Technologies, Gad Allon, Piedmont, Stex25, Viola Ventures, Catalio Capital Management.